iShares Gold Trust vs Medpace Holdings Inc — how do they compare? iShares Gold Trust trades at $82.84, while Medpace Holdings Inc trades at $598 (market cap $16.90B). The key difference: Medpace Holdings Inc is trading nearer its 52-week high, iShares Gold Trust nearer its low. Which is the better fit depends on your goals.
| IAU | MEDP | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Technology |
52-Week High | $101.57 | $620.59 |
52-Week Low | $62.49 | $393.42 |
Market Cap | — | $16.90B |
Enterprise Value | — | $16.52B |
Signals from Pluang's Aura AI — not financial advice
IAU, the iShares Gold Trust ETF, trades at $82.98 with a 0.57% daily gain amid bullish technical signals from moving averages. The ETF benefits from gold's recent momentum as spot gold reached two-month highs above $4,430/oz following cooling CPI data. While oscillators show bearish signals with RSI at overbought levels, institutional interest remains strong with Deane Retirement Strategies increasing its stake by 36.5% in the latest quarter.
Outlook remains positive as gold gains support from inflation dynamics, geopolitical tensions, and central bank buying. Key risks include potential Fed policy shifts and dollar strength. The 0.25% expense ratio makes IAU attractive for conservative investors seeking gold exposure with lower volatility compared to mining stocks.
MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.
MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.
Trailing returns across standard periods
Latest headlines on both assets
IAU is a physically backed ETF that seeks to reflect the performance of the price of gold. It provides a convenient and liquid way for investors to include gold in their portfolios as a potential hedge.
Read more on IAU →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →